Source: European Medicines Agency
Area: News
The European Medicines Agency (EMA) has announced the withdrawal of the application for a centralised marketing authorisation for voclosporin (Luveniq®), which was intended to be used for the treatment of patients with chronic non-infectious uveitis involving the posterior or intermediate segments of the eyes as characterised by a high degree of inflammation and in whom corticosteroids are inappropriate, do not provide adequate control, or cannot be tapered below 10mg/day.
The original application, submitted to the EMA in February 2010, received a negative opinion (Read more...)
Uncategorized